SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a leader in musculoskeletal care, today announced that its Continuum® Acetabular System recently became the Company's best-selling hip construct. Introduced in late 2009, the Continuum Acetabular System provides surgeons with options to choose the bearing technology that best meets the unique needs of each patient.
The Continuum System leverages the clinical success of a number of Zimmer's technologies. Continuum Shells are made with Zimmer's proprietary Trabecular Metal(TM) Technology, a porous metal biomaterial with a three dimensional structure and mechanical characteristics similar to those of cancellous bone. The outstanding performance of Trabecular Metal Material is supported by over thirteen years of clinical history and more than 100 peer reviewed publications. The Continuum System's alternative bearing options incorporate Zimmer's Metasul® Metal-on-Metal Articulation technology, supported by more than twenty years of clinical experience, Longevity® Highly Crosslinked Polyethylene, which is highly resistant to wear and aging and is supported by more than ten years of clinical experience, and BIOLOX® delta Ceramic Technology (BIOLOX® delta Ceramic is a trademark of CeramTec AG), which exhibits low wear and high fracture resistance.
"The Continuum System draws upon the clinical success of a number of our leading technology platforms," said Jeff McCaulley, President, Zimmer Reconstructive. "With a range of sizes and bearing configurations, surgeons are able to customize the system to meet the unique needs of their patients. We are excited by the progress this system has made in the last year and expect the Continuum System to become a keystone offering in our Hip business."
Zimmer will showcase the Continuum Acetabular System in its exhibit at the 2011 American Academy of Orthopaedic Surgeons (AAOS) annual meeting. To learn more, visit http://www.zimmer.com/.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2010 sales were approximately $4.2 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
Zimmer Holdings, Inc.
CONTACT: Media: Garry R. Clark, +1-574-372-4493,
garry.clark@zimmer.com, Investors: Paul G. Blair, +1-574-371-8042,
paul.blair@zimmer.com
Web Site: http://www.zimmer.com/
